1
|
Langabeer SE. Noncanonical CALR variants. Am J Clin Pathol 2024; 161:519. [PMID: 38124547 DOI: 10.1093/ajcp/aqad170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Accepted: 11/15/2023] [Indexed: 12/23/2023] Open
|
2
|
Langabeer SE. The JAK2 V617F mutation and childhood type1 diabetic nephropathy? Biomed Chromatogr 2024; 38:e5786. [PMID: 37994171 DOI: 10.1002/bmc.5786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Revised: 10/31/2023] [Accepted: 11/03/2023] [Indexed: 11/24/2023]
|
3
|
Langabeer SE, Burke Á. Persisting with persistent thrombocytosis. Int J Lab Hematol 2023; 45:816-817. [PMID: 37218366 DOI: 10.1111/ijlh.14105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Accepted: 05/11/2023] [Indexed: 05/24/2023]
Affiliation(s)
| | - Áine Burke
- Department of Haematology, Sligo University Hospital, Sligo, Ireland
| |
Collapse
|
4
|
Langabeer SE. Monoclonal gammopathy and myeloproliferative neoplasm molecular diagnostics. Hematol Transfus Cell Ther 2023:S2531-1379(23)00163-3. [PMID: 37659858 DOI: 10.1016/j.htct.2023.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 05/15/2023] [Accepted: 07/24/2023] [Indexed: 09/04/2023] Open
|
5
|
Andrews C, Conneally E, Langabeer SE. Molecular diagnostic criteria of myeloproliferative neoplasms. Expert Rev Mol Diagn 2023; 23:1077-1090. [PMID: 37999991 DOI: 10.1080/14737159.2023.2277370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 10/26/2023] [Indexed: 11/26/2023]
Abstract
INTRODUCTION Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by the driver mutations JAK2, CALR, and MPL. These mutations cause constitutive activation of JAK-STAT signaling, which is central to pathogenesis of MPNs. Next-generation sequencing has further expanded the molecular landscape allowing for improved diagnostics, prognostication, and targeted therapy. AREAS COVERED This review aims to address current understanding of the molecular diagnosis of MPN not only through improved awareness of the driver mutations but also the disease modifying mutations. In addition, other genetic factors such as clonal hematopoiesis of indeterminate potential (CHIP), order of mutation, and mutation co-occurrence are discussed and how these factors influence disease initiation and ultimately progression. How this molecular information is incorporated into risk stratification models allowing for earlier intervention and targeted therapy in the future will be addressed further. EXPERT OPINION The genomic landscape of the MPN has evolved in the last 15 years with integration of next-generation sequencing becoming the gold standard of MPN management. Although diagnostics and prognostication have become more personalized, additional studies are required to translate these molecular findings into targeted therapy therefore improving patient outcomes.
Collapse
Affiliation(s)
- Claire Andrews
- Department of Haematology, St. Vincent's University Hospital, Dublin, Ireland
| | | | | |
Collapse
|
6
|
Langabeer SE, Jones A, Conneally E, Enright H, Murphy P, Perera K, Quinn J, Thornton P. Frequency and driver mutation diversity of concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm. Int J Hematol 2023; 117:941-942. [PMID: 37099082 DOI: 10.1007/s12185-023-03611-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 03/06/2023] [Accepted: 04/19/2023] [Indexed: 04/27/2023]
Affiliation(s)
- Stephen E Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, D08 W9RT, Ireland.
| | - Alfred Jones
- Department of Haematology, Beaumont Hospital, Dublin, Ireland
| | | | - Helen Enright
- Department of Haematology, Tallaght University Hospital, Dublin, Ireland
| | - Philip Murphy
- Department of Haematology, Beaumont Hospital, Dublin, Ireland
| | - Kanthi Perera
- Department of Haematology, Midlands Regional Hospital, Tullamore, Ireland
| | - John Quinn
- Department of Haematology, Beaumont Hospital, Dublin, Ireland
| | | |
Collapse
|
7
|
Langabeer SE. BCR::ABL1 screening is not indicated in patients with splenomegaly without neutrophilia and/or basophilia. J Clin Pathol 2023; 76:413. [PMID: 36958819 DOI: 10.1136/jcp-2023-208864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Accepted: 03/16/2023] [Indexed: 03/25/2023]
|
8
|
Langabeer SE. Pyoderma gangrenosum and myeloproliferative neoplasms. Clin Exp Dermatol 2023; 48:555-556. [PMID: 36702807 DOI: 10.1093/ced/llad037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 01/26/2023] [Indexed: 01/28/2023]
Abstract
Pyoderma gangrenosum can be associated with haematological malignancies but rarely a myeloproliferative neoplasm. A review of requests for molecular detection of myeloproliferative neoplasm driver mutations in patients with pyoderma gangrenosum was performed and revealed that testing for these mutations is unwarranted in cases where there are no clinical, haematological or morphological features of a myeloproliferative neoplasm present.
Collapse
|
9
|
Langabeer SE. A temporal cluster of acute promyelocytic leukemia. EXCLI J 2023; 22:67-69. [PMID: 36814853 PMCID: PMC9939783 DOI: 10.17179/excli2022-5676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Figures] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 12/19/2022] [Indexed: 02/24/2023]
Affiliation(s)
- Stephen E. Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland,*To whom correspondence should be addressed: Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; Phone: +353-1-4162413, Fax: +353-1-4103513, E-mail:
| |
Collapse
|
10
|
Langabeer SE. Screening for Latent Polycythemia Vera in Renal Cell Carcinoma-Associated Erythrocytosis. J Kidney Cancer VHL 2023; 10:26-27. [PMID: 37123102 PMCID: PMC10130908 DOI: 10.15586/jkcvhl.v10i1.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 03/21/2023] [Indexed: 05/02/2023] Open
Affiliation(s)
- Stephen E. Langabeer
- Author for correspondence: Stephen E. Langabeer, PhD, FRCPath, Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James’s Hospital, Dublin, D08 W9RT, Ireland.
| |
Collapse
|
11
|
Langabeer SE. Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation? Technol Cancer Res Treat 2023; 22:15330338231179561. [PMID: 37312522 DOI: 10.1177/15330338231179561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023] Open
Affiliation(s)
- Stephen E Langabeer
- Cancer Molecular Diagnostics, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
| |
Collapse
|
12
|
Langabeer SE, Macleod S, Bhreathnach Ú, Fadalla K. Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation. Case Rep Hematol 2023; 2023:6673144. [PMID: 37123466 PMCID: PMC10139808 DOI: 10.1155/2023/6673144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 04/12/2023] [Accepted: 04/15/2023] [Indexed: 05/02/2023] Open
Abstract
Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the BCR::ABL1 tyrosine kinase domain (KDM) and of which the majority of which occur at seven codons within this region. A case of CML is described in which presence of a rare D363G BCR::ABL1 KDM resulted in a suboptimal response to frontline imatinib. Switching to dasatinib resulted in achieving a sustained major molecular response that was maintained after a subsequent switch to bosutinib due to the side effects. Reporting of such cases is important for the future management of any CML patients with this rare mutation.
Collapse
Affiliation(s)
| | - Stuart Macleod
- Department of Haematology, St. Vincent's University Hospital, Dublin D04T6F4, Ireland
| | - Úna Bhreathnach
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08W9RT, Ireland
| | - Kamal Fadalla
- Department of Haematology, St. Vincent's University Hospital, Dublin D04T6F4, Ireland
| |
Collapse
|
13
|
Langabeer SE. Absence of JAK2 V617F-mutated polycythemia vera in obstructive sleep apnea-associated erythrocytosis. Sleep Med X 2022; 4:100058. [PMID: 36299528 PMCID: PMC9589194 DOI: 10.1016/j.sleepx.2022.100058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 10/10/2022] [Indexed: 11/05/2022] Open
Affiliation(s)
- Stephen E. Langabeer
- Corrresponding author. Cancer Molecular Diagnostics, St. James's Hospital, Dublin, D08 W9RT, Ireland.
| |
Collapse
|
14
|
White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela JM, Cerveira N, Cochaux P, Colomer D, Coriu D, Diamond J, Dietz C, Dulucq S, Engvall M, Franke GN, Gineikiene-Valentine E, Gniot M, Gómez-Casares MT, Gottardi E, Hayden C, Hayette S, Hedblom A, Ilea A, Izzo B, Jiménez-Velasco A, Jurcek T, Kairisto V, Langabeer SE, Lion T, Meggyesi N, Mešanović S, Mihok L, Mitterbauer-Hohendanner G, Moeckel S, Naumann N, Nibourel O, Oppliger Leibundgut E, Panayiotidis P, Podgornik H, Pott C, Rapado I, Rose SJ, Schäfer V, Touloumenidou T, Veigaard C, Venniker-Punt B, Venturi C, Vigneri P, Vorkinn I, Wilkinson E, Zadro R, Zawada M, Zizkova H, Müller MC, Saussele S, Ernst T, Machova Polakova K, Hochhaus A, Cross NCP. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia 2022; 36:1834-1842. [PMID: 35614319 PMCID: PMC9252906 DOI: 10.1038/s41375-022-01607-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Revised: 05/06/2022] [Accepted: 05/12/2022] [Indexed: 11/17/2022]
Abstract
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1IS and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.
Collapse
Affiliation(s)
- Helen E White
- Faculty of Medicine, University of Southampton, Southampton, UK.,Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK
| | - Matthew Salmon
- Faculty of Medicine, University of Southampton, Southampton, UK.,Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK
| | - Francesco Albano
- Department of Emergency and Organ Transplantation (D.E.T.O.)-Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | | | - Stefan Balabanov
- Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Gueorgui Balatzenko
- Laboratory of Medical Genetics National Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria
| | - Gisela Barbany
- Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
| | - Jean-Michel Cayuela
- Laboratory of Hematology, University Hospital Saint-Louis, Université de Paris, Paris, France
| | - Nuno Cerveira
- Department of Genetics and Research Centre, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Pascale Cochaux
- Department of Molecular Hemato-Oncology, LHUB-ULB, Brussels, Belgium
| | - Dolors Colomer
- Pathology Department, Hospital Clinic, Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain
| | - Daniel Coriu
- Fundeni Clinical Institute, Hematology Department, Bucharest, Romania.,Hematology Department, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
| | - Joana Diamond
- Laboratório de Hemato-Oncologia-LHO Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal
| | - Christian Dietz
- Institute for Hematology and Oncology (IHO GmbH), Mannheim, Germany
| | - Stéphanie Dulucq
- University Hospital of Bordeaux, Laboratory of Hematology, Haut Lévêque Hospital, Pessac, France
| | - Marie Engvall
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - Georg N Franke
- University of Leipzig Medical Center, Department for Hematology, Cellular Therapies and Hemostaseology, Leipzig, Germany
| | | | - Michal Gniot
- Poznan University of Medical Sciences, Department of Hematology and Bone Marrow Transplantation, Poznan, Poland
| | - María Teresa Gómez-Casares
- Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
| | - Enrico Gottardi
- Laboratory of Chemical and Clinical Analysis "Area 3" A.O.U San Luigi Gonzaga-Orbassano, Turin, Italy
| | - Chloe Hayden
- SIHMDS Hosted by Imperial College Healthcare NHS Trust at Hammersmith Hospital, London, UK
| | - Sandrine Hayette
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'Hématologie Biologique, Pierre-Bénite, France
| | - Andreas Hedblom
- Section of Molecular Diagnostics, Clinical Genetics, Region Skåne, Lund, Sweden
| | - Anca Ilea
- Ritus Biotec Laboratory, Codlea-Brasov, Romania.,Transilvania University, Brasov, Romania
| | - Barbara Izzo
- Department of Molecular Medicine and Medical Biotechnology University 'Federico II' and CEINGE-Advanced Biotechnologies, Naples, Italy
| | | | - Tomas Jurcek
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.,Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - Veli Kairisto
- Department of Genomics, Turku University Hospital Laboratories, Turku, Finland
| | | | - Thomas Lion
- Labdia Labordiagnostik/St. Anna Children´s Cancer Research Institute (CCRI), Vienna, Austria
| | - Nora Meggyesi
- Laboratory of Molecular Genetics, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary
| | - Semir Mešanović
- Pathology Department, University Clinical Center Tuzla, Policlinic for Laboratory Diagnostics, Tuzla, Bosnia and Herzegovina
| | - Luboslav Mihok
- Department of Medical Genetics, National Cancer Institute, Bratislava, Slovakia
| | | | | | - Nicole Naumann
- III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
| | | | | | - Panayiotis Panayiotidis
- Haematology Research Laboratory, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
| | - Helena Podgornik
- Department of Haematology, University Medical Centre Ljubljana, Ljubljana, Slovenia.,Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| | - Christiane Pott
- Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Germany
| | - Inmaculada Rapado
- Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Imas12, 28041, Madrid, Spain.,Hematological Malignancies Clinical Research Unit, CNIO, 28029, Madrid, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, 28029, Madrid, Spain
| | - Susan J Rose
- West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
| | - Vivien Schäfer
- Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
| | - Tasoula Touloumenidou
- Molecular Diagnostics Laboratory, Hematology Department and HCT Unit, George Papanicolaou General Hospital, Thessaloniki, Greece
| | - Christopher Veigaard
- HemoDiagnostic Laboratory, Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | | | - Claudia Venturi
- IRCSS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy
| | - Paolo Vigneri
- Department of Clinical and Experimental Medicine, Center of Experimental Oncology and Hematology, University of Catania, Catania, Italy
| | - Ingvild Vorkinn
- Molecular Hemapathology, Oslo University Hospital, Oslo, Norway
| | - Elizabeth Wilkinson
- Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals, Leeds, UK
| | - Renata Zadro
- University Hospital Center Zagreb, Zagreb, Croatia
| | | | - Hana Zizkova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - Martin C Müller
- Institute for Hematology and Oncology (IHO GmbH), Mannheim, Germany
| | - Susanne Saussele
- III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
| | - Thomas Ernst
- Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
| | | | - Andreas Hochhaus
- Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
| | - Nicholas C P Cross
- Faculty of Medicine, University of Southampton, Southampton, UK. .,Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK.
| |
Collapse
|
15
|
Langabeer SE. Testosterone, erythrocytosis and the JAK2 V617 F mutation. Ann Clin Biochem 2022; 59:212-213. [PMID: 35090357 DOI: 10.1177/00045632221077867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Langabeer SE. Screening for latent polycythemia vera in chronic obstructive pulmonary disease-associated erythrocytosis. Respir Med Res 2022; 81:100914. [DOI: 10.1016/j.resmer.2022.100914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Accepted: 04/16/2022] [Indexed: 10/18/2022]
|
17
|
Lee-Tokar L, Kearney L, Langabeer SE. Detection of JAK2 Exon 12 Mutations in Suspected Polycythemia Vera by Next-Generation Sequencing. Clin Lab 2022; 68. [PMID: 35023693 DOI: 10.7754/clin.lab.2021.210510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
18
|
Langabeer SE. The eosinophilic variant of chronic myeloid leukemia. EXCLI J 2021; 20:1608-1609. [PMID: 35024018 PMCID: PMC8743830 DOI: 10.17179/excli2021-4462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 11/22/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Stephen E. Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland,*To whom correspondence should be addressed: Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; Phone: +353-1-4162413, Fax: +353-1-4103513, E-mail:
| |
Collapse
|
19
|
Bhreathnach Ú, Langabeer SE. Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization? Int J Lab Hematol 2021; 44:e67-e68. [PMID: 34585520 DOI: 10.1111/ijlh.13714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 09/09/2021] [Accepted: 09/15/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Úna Bhreathnach
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | | |
Collapse
|
20
|
Bhreathnach Ú, Kearney L, Langabeer SE. Prevalence of atypical BCR-ABL1 transcript types in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: implications for measurable residual disease. Hematol Transfus Cell Ther 2021; 44:130-131. [PMID: 34284978 PMCID: PMC8885372 DOI: 10.1016/j.htct.2021.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 04/12/2021] [Accepted: 05/26/2021] [Indexed: 11/17/2022] Open
Affiliation(s)
- Úna Bhreathnach
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | - Laura Kearney
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | | |
Collapse
|
21
|
Langabeer SE, O'Flynn DW, Cahill MR. Polycythemia vera emerging eighteen years after acute myeloid leukemia diagnosis. Blood Res 2021; 56:121-123. [PMID: 33986187 PMCID: PMC8246042 DOI: 10.5045/br.2021.2021040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Revised: 04/05/2021] [Accepted: 04/07/2021] [Indexed: 11/23/2022] Open
Affiliation(s)
| | - Derick W O'Flynn
- Department of Haematology, Cork University Hospital, Cork, Ireland
| | - Mary R Cahill
- Department of Haematology, Cork University Hospital, Cork, Ireland
| |
Collapse
|
22
|
Lee Tokar L, Crotty G, O'Keeffe D, Langabeer SE. Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden. Blood Cells Mol Dis 2021; 90:102593. [PMID: 34217938 DOI: 10.1016/j.bcmd.2021.102593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 06/25/2021] [Indexed: 10/21/2022]
Affiliation(s)
- Lisa Lee Tokar
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | - Gerard Crotty
- Department of Haematology, Midlands Regional Hospital, Tullamore, Ireland
| | - Denis O'Keeffe
- Department of Haematology, University Hospital Limerick, Limerick, Ireland
| | | |
Collapse
|
23
|
Faryal R, Lee Tokar L, Langabeer SE, Krawczyk J. CALR Mutation Underlying Silent Stroke. TH Open 2021; 5:e174-e175. [PMID: 34104855 PMCID: PMC8169313 DOI: 10.1055/s-0041-1728674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 01/26/2021] [Indexed: 11/25/2022] Open
Affiliation(s)
- Rehman Faryal
- Department of Haematology, Galway University Hospital, Galway, Ireland
| | - Lisa Lee Tokar
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | | | - Janusz Krawczyk
- Department of Haematology, Galway University Hospital, Galway, Ireland
| |
Collapse
|
24
|
Lee Tokar L, Kearney L, Langabeer SE. MPL exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm. EXCLI J 2021; 20:197-198. [PMID: 33628158 PMCID: PMC7898040 DOI: 10.17179/excli2021-3454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 01/28/2021] [Indexed: 11/27/2022]
Affiliation(s)
- Lisa Lee Tokar
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | - Laura Kearney
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | - Stephen E. Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland,*To whom correspondence should be addressed: Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; Phone: +353-1-4162413, Fax: +353-1-4103513, E-mail:
| |
Collapse
|
25
|
Langabeer SE, O'Brien D, McCarron S, Bacon CL, Vandenberghe E. Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia. J Clin Pathol 2020; 74:819. [PMID: 33372104 DOI: 10.1136/jclinpath-2020-207246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 12/15/2020] [Indexed: 11/03/2022]
Affiliation(s)
| | - David O'Brien
- Department of Haematology, St James's Hospital, Dublin, Ireland
| | - Sarah McCarron
- Cancer Molecular Diagnostics, St James's Hospital, Dublin, Ireland
| | - C Larry Bacon
- Department of Haematology, St James's Hospital, Dublin, Ireland
| | - Elisabeth Vandenberghe
- Cancer Molecular Diagnostics, St James's Hospital, Dublin, Ireland.,Department of Haematology, St James's Hospital, Dublin, Ireland
| |
Collapse
|
26
|
Langabeer SE, Bhreathnach Ú, Cahill MR, Elhassadi E, Ní Loingsigh S, Conneally E, Enright H. Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia? Blood Cells Mol Dis 2020; 87:102521. [PMID: 33254033 DOI: 10.1016/j.bcmd.2020.102521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Accepted: 11/13/2020] [Indexed: 11/29/2022]
Affiliation(s)
| | - Úna Bhreathnach
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | - Mary R Cahill
- Department of Haematology, Cork University Hospital, Cork, Ireland
| | - Ezzat Elhassadi
- Department of Haematology, University Hospital Waterford, Waterford, Ireland
| | | | | | - Helen Enright
- Department of Haematology, Tallaght University Hospital, Dublin, Ireland
| |
Collapse
|
27
|
Langabeer SE. CALR mutations in myeloproliferative neoplasms: An unfolding story. EXCLI J 2020; 19:1399-1400. [PMID: 33312103 PMCID: PMC7726487 DOI: 10.17179/excli2020-2985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Accepted: 10/12/2020] [Indexed: 11/10/2022]
Affiliation(s)
- Stephen E. Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland,*To whom correspondence should be addressed: Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; Phone: +353-1-4162413, Fax: +353-1-4103513, E-mail:
| |
Collapse
|
28
|
Kearney L, Lee Tokar L, Flynn C, Mykytiv V, Murphy K, Langabeer SE. Repeat JAK2 V617F testing in patients with suspected essential thrombocythaemia. J Clin Pathol 2020; 73:772. [PMID: 32646925 DOI: 10.1136/jclinpath-2020-206778] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 06/15/2020] [Indexed: 11/04/2022]
Affiliation(s)
| | | | | | | | - Karen Murphy
- St. Vincent's University Hospital, Dublin, Ireland
| | | |
Collapse
|
29
|
Langabeer SE. Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic. Ir J Med Sci 2020; 190:27-28. [PMID: 32638153 PMCID: PMC7340757 DOI: 10.1007/s11845-020-02303-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 07/02/2020] [Indexed: 01/20/2023]
|
30
|
Langabeer SE. Can post-splenectomy thrombocytosis mask essential thrombocythaemia? EXCLI J 2020; 19:773-774. [PMID: 32636730 PMCID: PMC7332784 DOI: 10.17179/excli2020-1474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 05/29/2020] [Indexed: 11/06/2022]
Affiliation(s)
- Stephen E. Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland,*To whom correspondence should be addressed: Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; Phone: +353-1-4162413, Fax: +353-1-4103513, E-mail:
| |
Collapse
|
31
|
Langabeer SE. Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how? Blood Res 2020; 55:67-68. [PMID: 32269979 PMCID: PMC7106119 DOI: 10.5045/br.2020.55.1.67] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Accepted: 03/07/2020] [Indexed: 11/17/2022] Open
|
32
|
Kearney L, Crampe M, Conneally E, Krawczyk J, Kumar S, Murphy PT, Mykytiv V, Ryan MF, Langabeer SE. Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia. Leuk Res Rep 2020; 13:100195. [PMID: 32211287 PMCID: PMC7082598 DOI: 10.1016/j.lrr.2020.100195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Accepted: 03/07/2020] [Indexed: 11/28/2022] Open
Affiliation(s)
- Laura Kearney
- Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James's Hospital, Dublin, D08 W9RT, Ireland
| | - Mireille Crampe
- Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James's Hospital, Dublin, D08 W9RT, Ireland
| | | | - Janusz Krawczyk
- Department of Haematology, Galway University Hospital, Galway, Ireland
| | - Senthil Kumar
- Department of Haematology, University Hospital Waterford, Waterford, Ireland
| | - Philip T Murphy
- Department of Haematology, Beaumont Hospital, Dublin, Ireland
| | - Vitaliy Mykytiv
- Department of Haematology, Cork University Hospital, Cork, Ireland
| | - Mary-Frances Ryan
- Department of Haematology, University Hospital Limerick, Limerick, Ireland
| | - Stephen E Langabeer
- Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James's Hospital, Dublin, D08 W9RT, Ireland
| |
Collapse
|
33
|
Affiliation(s)
- L Kearney
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 RX0X, Ireland
| | - M Crampe
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 RX0X, Ireland
| | - S E Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 RX0X, Ireland
| |
Collapse
|
34
|
Langabeer SE. The
JAK2
V617F mutation in breast cancer? Breast J 2020; 26:592. [DOI: 10.1111/tbj.13683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Accepted: 10/15/2019] [Indexed: 11/28/2022]
|
35
|
Langabeer SE. Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm. EXCLI J 2020; 19:86-88. [PMID: 32038118 PMCID: PMC7003640 DOI: 10.17179/excli2019-2063] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 01/06/2020] [Indexed: 01/07/2023]
|
36
|
Langabeer SE. Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia. Leuk Res Rep 2020; 14:100218. [PMID: 32817815 PMCID: PMC7426565 DOI: 10.1016/j.lrr.2020.100218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 07/27/2020] [Accepted: 08/05/2020] [Indexed: 11/18/2022] Open
|
37
|
Brodie R, Langabeer SE, Quinn J, McMenamin ME, Hayden PJ. Sorafenib for relapsed FLT3-ITD-positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis. Clin Case Rep 2019; 7:2579-2580. [PMID: 31893105 PMCID: PMC6935638 DOI: 10.1002/ccr3.2487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Revised: 08/20/2019] [Accepted: 09/17/2019] [Indexed: 11/24/2022] Open
Abstract
Relapse of FLT3-mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.
Collapse
Affiliation(s)
- Rachel Brodie
- Department of HaematologySt. James’s HospitalDublinIreland
| | | | - John Quinn
- Department of HaematologyBeaumont HospitalDublinIreland
| | | | | |
Collapse
|
38
|
Langabeer SE. The role of a low erythropoietin level in the diagnosis of JAK2 exon 12-mutated polycythemia vera. Blood Cells Mol Dis 2019; 80:102377. [PMID: 31655393 DOI: 10.1016/j.bcmd.2019.102377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Accepted: 10/18/2019] [Indexed: 10/25/2022]
|
39
|
Langabeer SE. Hypercalcemia as a biomarker of myeloproliferative neoplasms? EXCLI J 2019; 18:777-778. [PMID: 31611758 PMCID: PMC6785763 DOI: 10.17179/excli2019-1765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Accepted: 08/29/2019] [Indexed: 11/26/2022]
Affiliation(s)
- Stephen E. Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland,*To whom correspondence should be addressed: Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; Phone: +353-1-4103576, Fax: +353-1-4103513, E-mail:
| |
Collapse
|
40
|
Langabeer SE. Absence of Polycythemia Vera in Postrenal Transplant Erythrocytosis. EXP CLIN TRANSPLANT 2019; 18:657-658. [PMID: 31424356 DOI: 10.6002/ect.2019.0117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Stephen E Langabeer
- >From the Cancer Molecular Diagnostics Program, St. James's Hospital, Dublin, Ireland
| |
Collapse
|
41
|
Crampe M, Langabeer SE, O'Brien D, Ryan E, Bacon CL. Philadelphia chromosome-positive acute lymphoblastic leukemia with an e14a3 BCR-ABL1 fusion: The role of molecular monitoring. Hematol Oncol Stem Cell Ther 2019; 13:166-167. [PMID: 31158331 DOI: 10.1016/j.hemonc.2019.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 03/08/2019] [Accepted: 04/28/2019] [Indexed: 10/26/2022] Open
Affiliation(s)
- Mireille Crampe
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland
| | | | - David O'Brien
- Department of Haematology, St. James's Hospital, Dublin, Ireland
| | - Eileen Ryan
- Department of Haematology, St. James's Hospital, Dublin, Ireland
| | - C Larry Bacon
- Department of Haematology, St. James's Hospital, Dublin, Ireland
| |
Collapse
|
42
|
Langabeer SE. The mutational landscape of atypical chronic myeloid leukemia. EXCLI J 2019; 18:256-258. [PMID: 31217789 PMCID: PMC6558506 DOI: 10.17179/excli2019-1246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 04/04/2019] [Indexed: 01/24/2023]
|
43
|
|
44
|
Langabeer SE. The JAK2 V617F mutation in retinal vein or artery occlusion. EXCLI J 2019; 18:127-128. [PMID: 30956644 PMCID: PMC6449673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 02/27/2019] [Indexed: 12/05/2022]
Affiliation(s)
- Stephen E. Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland,*To whom correspondence should be addressed: Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland; Phone: +353-1-4103576, Fax: +353-1-4103513, E-mail:
| |
Collapse
|
45
|
Langabeer SE, Haslam K, Crampe M, MacDonagh B, McHugh J. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia. Exp Oncol 2019; 41:82-83. [PMID: 30932408 DOI: 10.32471/exp-oncology.2312-8852.vol-41-no-1.12685] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- S E Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 E9P6, Ireland
| | - K Haslam
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 E9P6, Ireland
| | - M Crampe
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 E9P6, Ireland
| | - B MacDonagh
- Department of Haematology, Tallaght University Hospital, Dublin D24 NR0A, Ireland
| | - J McHugh
- Department of Haematology, Tallaght University Hospital, Dublin D24 NR0A, Ireland
| |
Collapse
|
46
|
Langabeer SE. Aquagenic pruritus and the JAK2 V617F mutation. Clin Exp Dermatol 2018; 44:e33. [PMID: 30578575 DOI: 10.1111/ced.13872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/15/2018] [Indexed: 11/29/2022]
Affiliation(s)
- S E Langabeer
- Cancer Molecular Diagnostics, St James's Hospital, Dublin, D08 RX0X, Ireland
| |
Collapse
|
47
|
Langabeer SE. The JAK2 V617F mutation in lung cancer: caveat emptor. Exp Oncol 2018; 40:343-344. [PMID: 30593755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- S E Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 E9P6, Ireland
| |
Collapse
|
48
|
Langabeer SE. Incidental abnormal bone marrow signal on magnetic resonance imaging and reflexive testing for the JAK2 V617F mutation. Quant Imaging Med Surg 2018; 8:881-882. [PMID: 30306066 DOI: 10.21037/qims.2018.08.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
49
|
|
50
|
Atkinson E, Bakri M, Hayat A, Langabeer SE. Anagrelide and the CALR mutation allele burden in essential thrombocythemia. Exp Oncol 2018; 40:152-153. [PMID: 29949532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Affiliation(s)
- E Atkinson
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 E9P6, Ireland
| | - M Bakri
- Department of Haematology, University Hospital Galway, Galway H91 YR71, Ireland
| | - A Hayat
- Department of Haematology, University Hospital Galway, Galway H91 YR71, Ireland
| | - S E Langabeer
- Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 E9P6, Ireland
| |
Collapse
|